(+)-4-(4'-Chloro-biphenyl-4-yl)-4-oxo-2-[2-(4-oxo-4H-benzo[d][1,2,3]triazin-3-yl)-ethyl]-butyricacid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (+)-4-(4'-Chloro-biphenyl-4-yl)-4-oxo-2-[2-(4-oxo-4H-benzo[d][1,2,3]triazin-3-yl)-ethyl]-butyricacid
• 英文别名: α-[2-(4'-chloro[1,1'-biphenyl]-4-yl)-2-oxoethyl]-4-oxo-1,2,3-benzotriazine-3(4H)-butanoic acid；4-[4-(4-Chlorophenyl)phenyl]-4-oxo-2-[2-(4-oxo-1,2,3-benzotriazin-3-yl)ethyl]butanoic acid
• 化学式: C₂₅H₂₀ClN₃O₄
• 分子量: 461.904
• InChiKey: FPEDTAYRGKBCKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  99.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (+)-4-(4'-Chloro-biphenyl-4-yl)-4-oxo-2-[2-(4-oxo-4H-benzo[d][1,2,3]triazin-3-yl)-ethyl]-butyricacid 生成 (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-[2-(4-oxo-1,2,3-benzotriazin-3-yl)ethyl]butanoic acid 、
  参考文献：
  名称：

  INHIBITION OF MATRIX METALLOPROTEASES BY SUBSTITUTED BIARYL OXOBUTYRIC ACIDS

  摘要：

  公开号：

  EP0923530B1
• 作为产物：
  描述：

  Ditert-butyl 2-[2-[4-(4-chlorophenyl)phenyl]-2-oxoethyl]-2-[2-(4-oxo-1,2,3-benzotriazin-3-yl)ethyl]propanedioate 在 盐酸 作用下， 以 水 为溶剂， 反应 10.0h， 生成 (+)-4-(4'-Chloro-biphenyl-4-yl)-4-oxo-2-[2-(4-oxo-4H-benzo[d][1,2,3]triazin-3-yl)-ethyl]-butyricacid
  参考文献：
  名称：

  INHIBITION OF MATRIX METALLOPROTEASES BY SUBSTITUTED BIARYL OXOBUTYRIC ACIDS

  摘要：

  公开号：

  EP0923530B1

文献信息

• Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
  申请人：Bayer Aktiengesellschaft

  公开号：EP1031349A1

  公开（公告）日：2000-08-30

  Use of substituted 4-Biarylbutyric and 5-Biarylpentanoic Acid Derivatives for the Treatment of Cerebral Diseases, pharmaceutical compositions containing them, and a process for using them. The compounds of the invention have the generalized formula         (T)xA-B-D-E-CO2H wherein A is an aryl or heteroaryl rings; B is an aryl or heteroaryl ring or a bond; each T is a substituent group; x is 0, 1, or 2; the group D represents 〉C=O , or the group E represents a two or three carbon chain bearing one to three substituent groups which are independent or are involved in ring formation, possible structures being shown in the text and claims; and each of the substituents on E is an independent substituent; and include pharmaceutically acceptable salts thereof.

  使用替代的4-联苯丁酸和5-联苯戊酸衍生物治疗脑部疾病，包含它们的药物组合物，以及使用它们的方法。 该发明的化合物具有一般化学式         (T)xA-B-D-E-CO2H 其中A是芳基或杂环芳基；B是芳基或杂环芳基或键；每个T是取代基；x为0、1或2；D代表〉C=O，或 E代表一个带有一个到三个取代基的两个或三个碳链，这些取代基是独立的或参与环形成，可能的结构在文本和权利要求中显示；E上的每个取代基都是独立的取代基；并包括其药用盐。
• Inhibition of matrix metalloproteases by substitued biaryl oxobutyric acides
  申请人：——

  公开号：US20020042418A1

  公开（公告）日：2002-04-11

  Matrix metalloprotease inhibiting compounds, pharmaceutical compositions thereof and a method of disease treatment using such compounds are presented. The compounds of the invention have the generalized formulas: 1 wherein r is 0-2, T is selected from 2 and R 40 is a mono- or bi-heterocyclic structure. These compounds are useful for inhibiting matrix metalloproteases and, therefore, combating conditions to which MMP's contribute, such as osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal disease, corneal ulceration, proteinuria, aneurysmal aortic disease, dystrophobic epidermolysis, bullosa, conditions leading to inflammatory responses, osteopenias mediated by MMP activity, tempero mandibular joint disease, demyelating diseases of the nervous system, tumor metastasis or degenerative cartilage loss following traumatic joint injury, and coronary thrombosis from athrosclerotic plaque rupture. The present invention also provides pharmaceutical compositions and methods for treating such conditions.

  本发明提供了抑制基质金属蛋白酶的化合物、其制药组合物以及使用这些化合物的疾病治疗方法。该发明的化合物具有以下通用式：其中r为0-2，T选自2，R40是单环或双环杂环结构。这些化合物有助于抑制基质金属蛋白酶，从而对抗MMP所贡献的疾病，如骨关节炎、类风湿性关节炎、化脓性关节炎、牙周病、角膜溃疡、蛋白尿、动脉瘤性主动脉疾病、营养不良性表皮松解性水疱病、导致炎症反应的疾病、MMP活性介导的骨质疏松、颞下颌关节疾病、神经系统脱髓鞘性疾病、肿瘤转移或创伤性关节损伤后的退行性软骨丢失以及由动脉粥样硬化斑块破裂引起的冠状动脉血栓形成。本发明还提供了治疗这些疾病的制药组合物和方法。
• Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids
  申请人：——

  公开号：US20020042417A1

  公开（公告）日：2002-04-11

  Matrix metalloprotease inhibiting compounds, pharmaceutical compositions thereof and a method of disease treatment using such compounds are presented. The compounds of the invention have the generalized formulas: 1 wherein r is 0-2, T is selected from 2 and R 40 is a mono- or bi-heterocyclic structure. These compounds are useful for inhibiting matrix metalloproteases and, therefore, combating conditions to which MMP's contribute, such as osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal disease, corneal ulceration, proteinuria, aneurysmal aortic disease, dystrophobic epidermolysis, bullosa, conditions leading to inflammatory responses, osteopenias mediated by MMP activity, tempero mandibular joint disease, demyelating diseases of the nervous system, tumor metastasis or degenerative cartilage loss following traumatic joint injury, and coronary thrombosis from athrosclerotic plaque rupture. The present invention also provides pharmaceutical compositions and methods for treating such conditions.

  本发明提供了抑制基质金属蛋白酶的化合物，以及包含这些化合物的制药组合物和使用这些化合物治疗疾病的方法。该发明的化合物具有一般公式：其中r为0-2，T选自2，R40为单环或双环杂环结构。这些化合物对于抑制基质金属蛋白酶是有用的，因此可以用于对抗MMP参与的疾病，如骨关节炎、类风湿性关节炎、化脓性关节炎、牙周病、角膜溃疡、蛋白尿、动脉瘤性主动脉疾病、营养不良性表皮松解性水疱病、导致炎症反应的疾病、由MMP活性介导的骨质疏松、颞颌关节疾病、神经系统的脱髓鞘性疾病、肿瘤转移或创伤性关节损伤后的退行性软骨丢失以及由动脉粥样硬化斑块破裂导致的冠状动脉血栓形成。本发明还提供了治疗这些疾病的制药组合物和方法。
• USE OF SUBSTITUTED 4-BIARYLBUTYRIC AND 5-BIARYLPENTANOIC ACID DERIVATIVES FOR THE TREATMENT OF CEREBRAL DISEASES
  申请人：Bayer Aktiengesellschaft

  公开号：EP1087761A2

  公开（公告）日：2001-04-04
• US6225314B1
  申请人：——

  公开号：US6225314B1

  公开（公告）日：2001-05-01